{"id":"W2810134512","doi":"10.1200/jco.2017.35.15_suppl.tps4594","title":"Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Axitinib; Medicine; Sunitinib; Avelumab; Internal medicine; Renal cell carcinoma; Tyrosine-kinase inhibitor; Oncology; Gastroenterology; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775897,0.001236991,0.002181598,0.0004282623,0.0004418955,0.001584974,0.001179129,0.001497846,0.00758601],"category_scores_gemma":[0.0009786638,0.0006046811,0.002937139,0.0004450328,0.0006076915,0.001042315,0.0003527502,0.003563037,0.00151076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001447705,"about_ca_system_score_gemma":0.001759536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00133401,"about_ca_topic_score_gemma":0.004839702,"domain_scores_codex":[0.9996548,0.0001548622,0.00001686933,0.0000681557,0.00004144202,0.00006385707],"domain_scores_gemma":[0.9993184,0.00009774955,0.0001703123,0.00005160076,0.00004300371,0.0003189269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8430004,0.04172362,0.003592853,0.002093919,0.003443975,0.0001912375,0.0002182951,0.002396354,0.01691704,0.0003147958,0.005624098,0.0804833],"study_design_scores_gemma":[0.8137352,0.1698384,0.008391376,0.00008792115,0.00109832,0.000379085,0.00005387598,0.001264722,0.00176677,0.0003184009,0.003029962,0.00003600385],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768683,0.00828032,0.0007518523,0.001207904,0.0004016649,0.004156015,0.003327512,0.0002891658,0.004717221],"genre_scores_gemma":[0.978467,0.004465105,0.002001139,0.002027501,0.000242159,0.002814783,0.003943881,0.00006573784,0.005972709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00758601,"threshold_uncertainty_score":0.02537769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1676942709446262,"score_gpt":0.4735742379567842,"score_spread":0.305879967012158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}